SYM FINANCIAL Corp Lowers Stock Holdings in Exelixis, Inc. $EXEL

SYM FINANCIAL Corp trimmed its stake in Exelixis, Inc. (NASDAQ:EXEL) by 10.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,500 shares of the biotechnology company’s stock after selling 739 shares during the period. SYM FINANCIAL Corp’s holdings in Exelixis were worth $286,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in EXEL. Hemington Wealth Management raised its holdings in shares of Exelixis by 211.3% in the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 522 shares in the last quarter. Byrne Asset Management LLC raised its holdings in shares of Exelixis by 129.0% in the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 400 shares in the last quarter. Family Legacy Financial Solutions LLC bought a new stake in shares of Exelixis in the 2nd quarter valued at about $33,000. Bartlett & CO. Wealth Management LLC bought a new stake in shares of Exelixis in the 1st quarter valued at about $37,000. Finally, Costello Asset Management INC bought a new stake in shares of Exelixis in the 1st quarter valued at about $39,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Stock Performance

NASDAQ:EXEL opened at $39.99 on Tuesday. The company has a fifty day moving average of $38.72 and a two-hundred day moving average of $40.15. The stock has a market capitalization of $10.77 billion, a PE ratio of 19.23, a P/E/G ratio of 0.78 and a beta of 0.38. Exelixis, Inc. has a fifty-two week low of $28.05 and a fifty-two week high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.84 earnings per share. Research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on EXEL. JMP Securities restated a “market outperform” rating and issued a $50.00 price target on shares of Exelixis in a report on Tuesday, July 29th. Zacks Research downgraded shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. HC Wainwright cut their price objective on shares of Exelixis from $53.00 to $46.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Leerink Partnrs raised shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 21st. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.53.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.